ArticleBMC veterinary research2025
Characterization and enzymatic function of thioredoxin glutathione reductase in Orientobilharzia turkestanicum isolated from Xizang.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Screening Novel Furoxan Derivatives as Potential Inhibitors Targeting Thioredoxin Glutathione Reductase ofPharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Orientobilharziasis, caused by Orientobilharzia turkestanicum, is a zoonotic parasitic disease that leads to significant economic losses in livestock and cercarial dermatitis in humans. This study focuses on the molecular characterization and functional analysis of thioredoxin glutathione reductase (TGR) from O. turkestanicum, a key enzyme involved in the parasite’s antioxidant defense system. The full-length O. turkestanicum thioredoxin glutathione reductase (OtTGR) cDNA and O. turkestanicum thioredoxin glutathione reductase with selenocysteine (OtTGRsec) were cloned and expressed as recombinant proteins in E. coli. Western blotting confirmed the specific immunoreactivity of rOtTGR with polyclonal antibodies, and immunohistochemistry revealed its predominant localization on the tegument of adult worms. Enzymatic activity assays demonstrated that rOtTGRsec possesses thioredoxin reductase, glutaredoxin, and glutathione reductase activities, with optimal activity under physiological pH and temperature conditions. RNA interference assays showed that siRNA3 effectively suppressed OtTGR expression in vitro, reducing mRNA levels by 46.1%. These findings highlight the critical role of OtTGR in parasite survival. Comparative with other trematodes, such as Schistosoma japonicum and Fasciola hepatica, suggests that OtTGR may serve as a promising target for vaccine or drug development. Although immune-protective studies were not feasible due to host incompatibility, the conserved role of TGR across trematodes underscores its potential for controlling orientobilharziasis. Future studies will explore the immunogenicity and protective efficacy of OtTGR to assess its candidacy as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.